US 12,480,034 B2
Extended release colloidal scale inhibitor
Ross Tomson, Houston, TX (US); Paula Guraieb, Houston, TX (US); Rangana Jayawickramage, Houston, TX (US); and Kyle Swanson, Houston, TX (US)
Assigned to CHAMPIONX LLC, Sugar Land, TX (US)
Appl. No. 17/599,373
Filed by Tomson Technologies LLC, Houston, TX (US)
PCT Filed Mar. 30, 2020, PCT No. PCT/US2020/025738
§ 371(c)(1), (2) Date Sep. 28, 2021,
PCT Pub. No. WO2020/205747, PCT Pub. Date Oct. 8, 2020.
Claims priority of provisional application 62/826,369, filed on Mar. 29, 2019.
Prior Publication US 2022/0145162 A1, May 12, 2022
Int. Cl. C09K 8/536 (2006.01); C09K 8/03 (2006.01); C09K 8/035 (2006.01); C09K 8/584 (2006.01); E21B 43/16 (2006.01)
CPC C09K 8/536 (2013.01) [C09K 8/032 (2013.01); C09K 8/035 (2013.01); C09K 8/584 (2013.01); E21B 43/16 (2013.01); C09K 2208/10 (2013.01)] 17 Claims
OG exemplary drawing
 
1. An aqueous solution comprising a plurality of nanoparticles dispersed throughout the aqueous solution, the nanoparticles comprising:
a hydrocarbon formation and/or well treatment additive chemically bound to the nanoparticles and releasable from the nanoparticles, silica, and at least one metal selected from a Column 2 metal, a Column 14 metal, a transition metal, or any combination thereof,
wherein the nanoparticles have an average particle size of less than 300 nm,
wherein the aqueous solution does not include a surfactant, and
wherein the nanoparticles do not precipitate out of the aqueous solution when subjected to a temperature of −20° C. to 200° C. and a pH of 5 to 9.